Wnt2 neutralizing antibodies seem to recall the immune response to the tumor through the activation of dendritic cells [242] and FAP-targeted chimeric antigen receptor T cells, leading to depletion of FAP + CAFs, revoking the pro-angiogenic CAFs-related effect [241]. The gene discussed is FAP; the disease is neoplasm.